Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases

Author(s): Oliesia Gonzalez Quiñones and Maria Bernadete Riemma Pierre*

Volume 19, Issue 1, 2019

Page: [5 - 16] Pages: 12

DOI: 10.2174/1568009618666180430125201

Price: $65

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) and particularly selective cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Cxb) are considered promising cancer chemopreventive for colon, breast, prostate, lung, and skin cancers. However, the clinical application to the prevention is limited by concerns about safety, potential to serious toxicity (mainly for healthy individuals), efficacy and optimal treatment regimen. Cxb exhibits advantages as potent antiinflammatory and gastrointestinal tolerance compared with conventional NSAID’s. Recent researches suggest that dermatological formulations of Cxb are more suitable than oral administration in the treatment of cutaneous disease, including skin cancer. To date, optimism has been growing regarding the exploration of the topical application of Cxb (in the prevention of skin cancers and treatment of cutaneous inflammation) or transdermal route reducing risks of systemic side effects.

Objective: This paper briefly summarizes our current knowledge of the development of the cutaneous formulations or delivery systems for Cxb as anti-inflammatory drug (for topical or transdermal application) as well its chemopreventive properties focused on skin cancer.

Conclusion: New perspectives emerge from the growing knowledge, bringing innovative techniques combining the action of Cxb with other substances or agents which act in a different way, but complementary, increasing the efficacy and minimizing toxicity.

Keywords: Celecoxib, skin inflammation, UVB-induced cancer, chemoprevention, formulations, Nonsteroidal antiinflammatory drugs (NSAIDs).

Graphical Abstract

[1]
Hilal-Dandan, R.; Brunton, L. Goodman and Gilman’s Manual of Pharmacology and Therapeutics, 2nd ed; Mc Graw Hill Education, 2014, pp. 879-913.
[2]
Sakamoto, C.; Soen, S. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in japan. Digestion, 2011, 83, 108-123.
[3]
Jarupongprapa, S.; Ussavasodhi, P.; Katchamart, W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non- selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systemic review and meta-analysis. J. Gastroenterol., 2013, 48(7), 830-838.
[4]
Chauhan, A.S.; Sridevi, S.; Chalsani, K.B.; Jain, A.K.; Jain, S.K.; Jain, N.K.; Diwan, P.V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release, 2003, 90(3), 335-343.
[5]
Lichtenberger, L.M. Where is the evidence that cyclooxigenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol., 2001, 61, 631-637.
[6]
Fischer, S.M.; Hawk, E.T.; Lubet, R.A. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev. Res. (Phila.), 2011, 4, 1728-1735.
[7]
Mennini, N.; Furlanetto, S.; Cirri, M.; Mura, P. Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex. Eur. J. Pharm. Biopharm., 2011, 80(1), 67-75.
[8]
Margulis-Goshen, K.; Kesselman, E.; Danino, D.; Magdassi, S. Formation of celecoxib nanoparticles from volatile microemulsions. Int. J. Pharm., 2010, 393, 230-237.
[9]
Soliman, S.M.; Abdel-Malak, N.S.; El-Gazayerley, O.N.; Abdel Rehim, A.A. Formulation of microemulsion gel systems for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity and skin irritation test. Drug Discov. Ther., 2010, 4(6), 459-471.
[10]
Shakeel, F.; Baboota, S.; Ahuja, A.; Ali, J.; Shafiq, S. Celecoxib nanoemulsion: Skin permeation mechanism and biovailability assesment. J. Drug Target., 2008, 16(10), 733-740.
[11]
Shakeel, F.; Baboota, S.; Ahuja, A.; Ali, J.; Shafiq, S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J. Nanobiotechnology, 2008, 6, 8.
[12]
Garti, N.; Avrahami, M.; Aserin, A. Improved solubilization of celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J. Colloid Interface Sci., 2009, 299(1), 352-365.
[13]
Subramanian, N.; Ghosal, S.K.; Moulik, S.P. Topical delivery of celecoxib using microemulsion. Acta Pol. Pharm., 2004, 61(5), 335-341.
[14]
Margulis-Goshen. Weitman, M.; Major, D.T.; Magdassi, S. Inhibition of crystallization and growth of celecoxib nanoparticles formed from volatile microemulsions. J. Pharm. Sci., 2011, 100(10), 4390-4400.
[15]
Deniz, A.; Sade, A.; Severcan, F.; Keskin, D.; Tezcaner, A.; Banerjee, S. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Biosci. Rep., 2010, 30(5), 365-373.
[16]
Nasr, M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral adminitration. AAPS PharmSciTech, 2010, 11(1), 85-89.
[17]
Paulson, S.K.; Hribar, J.D.; Liu, N.W.; Hajdu, E.; Bible, R.H.; Piergies, A.; Karim, A. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab. Dispos., 2000, 28(3), 308-314.
[18]
Malik, P.; Kadam, R.S.; Cheruvu, N.P.; Kompella, U.B. Hidrophilic produg approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Mol. Pharm., 2012, 9(3), 605-614.
[19]
Yener, G.; Gönüllü, U.; Uner, M.; Değim, T.; Araman, A. Effects of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin. Pharmazie, 2003, 58(5), 330-333.
[20]
Bachar, M.; Mandelbaum, A.; Portnaya, I.; Perlstein, H.; Even-Chen, S.; Barenholz, Y.; Danino, D. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. J. Control. Release, 2012, 160(2), 164-171.
[21]
Subramanian, N.; Ghosal, S.K.; Moulik, S.P. Enhanced in vitro percutaneous absorption and in vivo anti-inflamatory effect of a selective cyclooxygenase inhibitor using microemulsion. Drug Dev. Ind. Pharm., 2005, 31, 405-416.
[22]
Thakkar, H.; Kumar-Sharma, R.; Murthy, R.S. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D., 2007, 8(5), 275-285.
[23]
Rao, C.V.; Reddy, B.S. NSAIDs and Chemoprevention. Curr. Cancer Drug Targets, 2004, 4(1), 29-42.
[24]
Haroutiunian, S.; Drennan, D.A.; Lipman, G.A. Topical NSAID therapy for musculoskeletal pain. Pain Med., 2010, 11, 535-549.
[25]
Okyar, A.; Ozsoy, Y.; Gungor, S. Novel formulation approaches for dermal and transdermal delivery of non-steroidal antiinflammatory drugs, rheumatoid arthritis - treatment, intech, 2012; available from. http://www.intechopen.com/books/rheumatoid-arthritis-treatment/novel-formulation-approaches-for-dermaland-transdermal-delivery-of-non-steroidal-anti-inflammatory
[26]
Loh, T.Y.; Cohen, P.R. Ketoprofen-induced photoallergic dermatitis. Indian J. Med. Res., 2016, 144(6), 803-806.
[27]
Wu, X.; Patterson, S.; Hawk, E. Chemoprevention-history and general principles. Best Pract. Res. Clin. Gastroenterol., 2011, 25, 445-459.
[28]
Cahoon, E.K.; Rajaraman, P.; Alexander, B.H.; Doody, M.M.; Linet, M.S.; Freedman, D.M. Use of nonesteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the united states radiologic technologist study. Int. J. Cancer, 2012, 130(12), 2939-2948.
[29]
Khan, Z.; Khan, N.; Tiwari, R.P.; Sah, N.K.; Prasad, G.B.; Bisen, P.S. Biology of COX-2: An application in cancer therapeutics. Curr. Drug Targets, 2011, 12(7), 1082-1093.
[30]
Kim, T.H.; Jeong, Y.I.; Jin, S.G.; Pei, J.; Jung, T.Y.; Moon, K.S.; Kim, I.Y.; Kang, S.S.; Jung, S. Preparation of polylactide-co-glycolide nanoparticles incorparating celecoxib and their antitumor activity against brain tumor cells. Int. J. Nanomedicine, 2011, 6, 2621-2631.
[31]
Shamsher, A.A.; Charoo, N.A.; Rahman, Z.; Pillai, K.K.; Kohli, K. Tulsi oil as a potencial penetration enhancer for celecoxib transdermal gel formulations. Pharm. Dev. Technol., 2014, 19(1), 21-30.
[32]
Zhao, P.; Jiang, H.; Jiang, T.; Zhi, Z.; Wu, C.; Sun, C.; Zhang, J.; Wang, S. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy. Eur. J. Pharm. Sci., 2012, 45(5), 639-647.
[33]
Wan, F.; Bohr, A.; Maltesen, M.J.; Bjerregaard, S.; Foged, C.; Rantanen, J.; Yang, M. Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded PLGA microparticles via spray-drying. Pharm. Res., 2013, 30(4), 1065-1076.
[34]
Abu-Diak, O.A.; Jones, D.S.; Andrews, G.P. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol. Pharm., 2011, 8(4), 1362.
[35]
Cheng, S.Y.; Yuen, M.C.; Lam, P.L.; Gambari, R.; Wong, R.S.; Cheng, G.Y.; Lia, P.B.; Tong, S.W.; Chan, K.W.; Lau, F.Y.; Kok, S.H.; Lam, K.H.; Chui, C.H. Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib micropsules. Bioorg. Med. Chem. Lett., 2010, 20(14), 4147-4151.
[36]
Nasr, M. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats. AAPS PharmSciTech, 2013, 14(2), 719-726.
[37]
Patlolla, R.R.; Chougule, M.; Patel, A.R.; Jackson, T.; Tata, P.N.; Singh, M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release, 2010, 144(2), 233-241.
[38]
Ibrahim, M.M.; Abd-Elgawad, A.E.; Soliman, O.A.; Jablonski, M.M. Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release. J. Pharm. Sci., 2013, 102(3), 1036-1053.
[39]
Amrite, A.C.; Edelhauser, H.F.; Singh, S.R.; Kompella, U.B. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis., 2008, 14, 150-160.
[40]
Thakkar, H.P.; Murthy, R.R. Effect of cross-linking on the characteristics of the celecoxib loaded chitosan microspheres. Asian J. Pharm, 2008, 2, 246-251.
[41]
Quiñones, O.G.; Mata dos Santos, H.A.; Kibwila, D.M.; Leitão, A.; dos Santos Pyrrho, A.; Pádula, M.; Rosas, E.C.; Lara, M.G.; Pierre, M.B.R. In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib. Drug Dev. Ind. Pharm., 2014, 40(9), 1180-1189.
[42]
Sharma, R.; Mehra, G.R. Preparation, characterization, in vitro and in vivo evaluation of transdermal matrix films of celecoxib. Acta Pharm. Sci, 2011, 53, 67-76.
[43]
Alam, M.I.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A. Pharmacodymanic evaluation of proniosomal transdermal therapeutic gel containing celecoxib. Sci. Asia, 2010, 36, 305-311.
[44]
Joshi, M.; Patravale, V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm., 2008, 346, 124-132.
[45]
Baboota, S.; Shakeel, F.; Ahuja, A.; Ali, J.; Shafiq, S. Design, devolepment and evaluation of novel nanoemulsion formulations for transdermal potencial of celecoxib. Acta Pharm., 2007, 57, 315-332.
[46]
Desai, P.R.; Shah, P.P.; Patlolla, R.R.; Singh, M. Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm. Res., 2012, 29(9), 2587-2600.
[47]
Sharma, P.K.; Bajpai, M. Enhancement of solubility and stability of celecoxib using microemulsion based topical formulation. J. Pharm. Res., 2011, 4(7), 2216-2220.
[48]
Begum, M.Y.; Abbulu, K.; Sudhakar, M.; Jayaprakash, S. Studies on the development of celecoxib transdermal patches. Int. J. Pharm. Tech. Res., 2011, 3(3), 1609-1615.
[49]
Moreira, T.S.; de Sousa, V.P.; Pierre, M.B.R. A novel transdermal delivery system for the anti–inflamatory Lumiracoxib: Influence of Oleic Acid on in vitro percutaneous absorption and in vivo potencial cutaneous irritation. AAPS PharmSciTech, 2010, 11(2), 621-629.
[50]
Gibson, M. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Comercial Dosage Form. Volume 199, 2nd ed; Drugs and the Pharmaceuticals Sciences, 2009.
[51]
Khurana, S.; Bedi, P.M.; Jain, N.K. Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chem. Phys. Lipids, 2013, 176, 65-72.
[52]
Manconi, M.; Caddeo, C.; Sinico, C.; Valenti, D.; Mostallino, M.C.; Biggio, G.; Fadda, A.M. Ex vivo skin delivery of diclofenac by transcutol containing liposomes. Eur. J. Pharm. Biopharm., 2011, 78(1), 27-35.
[53]
Nokhodchi, A.; Sharabiani, K.; Rashidi, M.R.; Ghafourian, T. The effect of terpene concentrations on the skin penetration of diclofenac sodium. Int. J. Pharm., 2007, 335, 97-105.
[54]
Fetih, G.; Fathalla, D.; El-Badry, M. Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation. Drug Dev. Res., 2014, 75(4), 257-266.
[55]
Venkatesan, P.; Puwada, N.; Dash, R.; Prashanth Kumar, B.N.; Sarkar, D.; Azab, B.; Pathak, A.; Kundu, S.C.; Fisher, P.B.; Mandal, M. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials, 2011, 32(15), 3794-3806.
[56]
Bijman, M.N.; Hermelink, C.A.; van Berkel, P.A.; Laan, A.C.; Janmaat, M.L.; Peters, G.J.; Boven, E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol., 2008, 75(2), 427-437.
[57]
Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L.K.; Levin, B.; Godio, L.; Patterson, S.; Rodriguez-Bigas, M.A.; Jester, S.L.; King, K.L.; Schumacher, M.; Abbruzzese, J.; DuBois, R.N.; Hittelman, W.N.; Zimmerman, S.; Sherman, J.W.; Kelloff, G. The effect of celecoxib, a cyclooxigenase–2 inhibitors, in familial adenomatous polyposis. N. Engl. J. Med., 2000, 342(26), 1946-1952.
[58]
Kawamori, T.; Rao, C.V.; Seibert, K.; Reddy, B.S. Chemopreventive activity of celecoxib, a especific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 1998, 58(3), 409-412.
[59]
Saba, N.F.; Hurwitz, S.J.; Kono, S.A.; Yang, C.S.; Zhao, Y.; Chen, Z.; Sica, G.; Müller, S.; Moreno-Williams, R.; Lewis, M.; Grist, W.; Chen, A.Y.; Moore, C.E.; Owonikoko, T.K.; Ramalingam, S.; Beitler, J.J.; Nannapaneni, S.; Shin, H.J.; Grandis, J.R.; Khuri, F.R.; Chen, Z.G.; Shin, D.M. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev. Res. (Phila.), 2014, 7(3), 283-291.
[60]
Abrahão, A.C.; Giudice, F.S.; Sperandio, F.F.; Pinto Junior Ddos, S. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J. Oral Pathol. Med., 2013, 42(10), 793-798.
[61]
Kilic, A.; Schuchert, M.J.; Luketich, J.D.; Landreneau, R.J.; El-Hefnawy, T. Efficacy of signal pathway inhibitors alone and combination with cisplatin varies between human non–small cell lung cancer lines. J. Surg. Res., 2009, 154(1), 9-12.
[62]
Okada, T.; Takigawa, N.; Kishino, D.; Katayama, H.; Kuyama, S.; Sato, K.; Mimoto, J.; Ueoka, H.; Tanimoto, M.; Kiura, K. Selective cyclooxigenase-2 inhibitor prevents cisplatin-induced tmorigenesis in A/J Mice. Acta Med. Okayama, 2012, 66(3), 245-251.
[63]
Buckstein, R.; Kerbel, R.S.; Shaked, Y.; Nayar, R.; Foden, C.; Turner, R.; Lee, C.R.; Taylor, D.; Zhang, L.; Man, S.; Baruchel, S.; Stempak, D.; Bertolini, F.; Crump, M. High-dose celecoxib and metro- nomic “Low-dose” cyclophosphamide is an effective and safe therapy in patients with relapse and refractory agressive histology Non-Hodgkins lymphoma. Clin. Cancer Res., 2006, 12(17), 5190-5198.
[64]
Kim, S.H.; Kim, S.H.; Song, Y.C.; Song, Y.S. Celecoxib potentiates the anticancer effects of cisplastin on vulvar cancer cells independently of cyclooxigenase. Ann. N. Y. Acad. Sci., 2009, 1171, 635-641.
[65]
Chen, J.; Ran, Y.; Hong, C.; Chen, Z.; You, Y. Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expression COX-2 oncoprotein. Cytotchenology, 2010, 62(5), 431-438.
[66]
Li, W.Z.; Wang, X.Y.; Li, Z.G.; Zhang, J.H.; Ding, Y.Q. Celecoxib enhances the inhibitory effect of cispalstin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. J. Oral Pathol. Med., 2010, 39(7), 579-584.
[67]
Yu, L.; Chen, M.; Li, Z.; Wen, J.; Fu, J.; Guo, D.; Jiang, Y.; Wu, S.; Cho, C.H.; Liu, S. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma by reducing intracellular cisplatin accumulation. Mol. Pharmacol., 2011, 79(3), 608-617.
[68]
Mohammadianpanah, M.; Razmjou-Ghalaei, S.; Shafizad, A.; Ashouri-Taziani, Y.; Khademi, B.; Ahmadloo, N.; Ansari, M.; Omidvari, S.; Mosalaei, A.; Mosleh-Shirazi, M.A. Efficacy and safety of current chemoradiation with weekly cisplatin ± low–dose celecoxib in locally advanced un- differentiated nasopharygeal carcinoma: A phase II–III clinical trial. J. Cancer Res. Ther., 2011, 7(4), 442-447.
[69]
Cohen, S.; Efraim, A.N.; Levi-Schaffer, F.; Eliashar, R. The effect of hypoxia and cyclooxigenase inhibitors on nasal polyp derived fibroblasts. Am. J. Otolaryngol., 32, 564-573. 2011
[70]
Huang, K.H.; Kuo, K.L.; Chen, S.C.; Weng, T.I.; Chuang, Y.T.; Tsai, Y.C.; Pu, Y.S.; Chiang, C.K.; Liu, S.H. Down–regulation of glucose–regulated protein (GRP) 78 potentiates cytotoxic effects of celecoxib in human urothelial carcinoma cells. PLoS One, 2012, 7(3), e33615.
[71]
Sareddy, G.R.; Geeviman, K.; Ramulu, C.; Babu, P.P. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J. Neurooncol., 2012, 106(1), 99-109.
[72]
Chiu, L.C.; Tong, K.F.; Ooi, V.E. Cytostatic and cytotoxic effects of cyclooxigenase inhbitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed. Pharmacother., 2005, 59(Suppl. 2), S293-S297.
[73]
Gogas, H.; Polyzos, A.; Stavrinidis, I.; Frangia, K.; Tsoutsos, D.; Panagiotou, P.; Markopoulos, C.; Papadopoulos, O.; Pectasides, D.; Mantzourani, M.; Middleton, M.; Vaiopoulos, G.; Fountzilas, G. Temozolomide in combination with celecoxib in patients with advanced melanoma. a phase ii study of the Hellenic Cooperative Oncology Group. Ann. Oncol., 2006, 17(12), 1835-1841.
[74]
Pagliarulo, V.; Ancona, P.; Niso, M.; Colabufo, N.A.; Contino, M.; Cormio, L.; Azzariti, A.; Pagliarulo, A. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol. Cancer, 2013, 12, 47.
[75]
Kim, C.H.; Chung, C.W.; Lee, H.M. Kim do, H.; Kwak, T.W.; Jeong, Y.I.; Kang, D.H. Synergistic effects of 5-aminolevulinic acid based photodynamic therapy and celecoxib via oxidative stress in human cholangiocarcinoma cells. Int. J. Nanomedicine, 2013, 8, 2173-2186.
[76]
Song, J.; Chen, Q.; Xing, D. Enhanced apoptotic effects by downregulating Mcl-1: Evidence for the improvement of photodynamic therapy with Celecoxib. Exp. Cell Res., 2013, 319(10), 1491-1504.
[77]
Hyter, S.; Indra, A.K. Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis. FEBS Lett., 2013, 587(6), 529-541.
[78]
Lee, J.L.; Mukhtar, H.; Bickers, D.R.; Kopelovich, L.; Athar, M. Cyclooxygenase in the skin: pharmacological and toxicological implications. Toxicol. Appl. Pharmacol., 2003, 192(3), 294-306.
[79]
Hatton, J.L.; Parent, A.; Tober, K.L.; Hoppes, T.; Wulff, B.C.; Duncan, F.J.; Kusewitt, D.F.; VanBuskirk, A.M.; Oberyszyn, T.M. Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure. J. Invest. Dermatol., 2007, 127(6), 1507-1515.
[80]
Wilgus, T.A.; Koki, A.T.; Zweifel, B.S.; Kusewitt, D.F.; Rubal, P.A.; Oberyszyn, T.M. Inhbition of cutaneous ultraviolet light B–mediated inflamation and tumor formation with topical celecoxib treatment. Mol. Carcinog., 2003, 38(2), 49-58.
[81]
Cocoş, R.; Schipor, S.; Nicolae, I.; Thomescu, C.; Raicu, F. Role of COX-2 activity and CRP levels in patients with non–melanoma skin cancer. –765GC PTGS2 polymorphism and NMSC risk. Arch. Dermatol. Res., 2012, 304(5), 335-342.
[82]
Chun, K.S.; Langenbach, R. The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin. Mol. Carcinog., 2011, 5D(6), 439-448.
[83]
Buckman, S.Y.; Gresham, A.; Hale, P.; Hruza, G.; Anast, J.; Masferrer, J.; Pentland, A.P. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis, 1998, 19(5), 723-729.
[84]
Tober, K.L.; Wilgus, T.A.; Kusewitt, D.F. Thomas-Ahner, J.M.; Maruyama, T.; Oberyszyn, T.M. Importance of the EP1 receptor in cutaneuos UVB–Induced inflamation and tumor development. J. Invest. Dermatol., 2006, 126(1), 205-211.
[85]
Singh, T.; Katiyar, S.K. Green tea catechins reduce invasive potencial of human melanoma cells by targeting COX-2, PGE2 Receptors and Epithelial to Mesenchymal Transition. PLoS One, 2011, 6(10), e25224.
[86]
Singh, T.; Vaid, M.; Katiyar, N.; Sharma, S.; Katiyar, S.K. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the espressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors. Carcinogenesis, 2011, 32(1), 86-92.
[87]
Maglio, D.H.G.; Paz, M.L.; Cela, E.M.; Leoni, J. Cyclooxygenase-2 overexpression in non-melanoma skin cancer: molecular pathways involved as targets for prevention and treatment. skin cancers - risk factors, prevention and therapy, 2011, Prof. Caterina La Porta (Ed.), ISBN: 978- 953-307-722-2, InTech, Available from:. http://www.intechopen.com/books/skin-cancers-risk-factorsprevention-and-therapy/cyclooxygenase-2-overexpression-in-non-melanoma-skin-cancer-molecularpathways-involved-as-targets-f
[88]
Wilgus, T.A.; Ross, M.S.; Parrett, M.L.; Oberyszyn, T.M. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid, 2000, 62(4), 367-384.
[89]
Elmets, C.A.; Viner, J.L.; Pentland, A.P.; Cantrell, W.; Lin, H.Y.; Bailey, H.; Kang, S.; Linden, K.G.; Heffernan, M.; Duvic, M.; Richmond, E.; Elewski, B.E.; Umar, A.; Bell, W.; Gordon, G.B. Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. J. Natl. Cancer Inst., 2010, 102(24), 1835-1844.
[90]
Wulff, B.C.; Thomas-Ahner, J.M.; Schick, J.S.; Oberyszyn, T.M. Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosupresive drugs. Int. J. Cancer, 2010, 126(1), 11-18.
[91]
Karagece Yalçin, U.; Seçkın, S. The expression of p53 and cox-2 in basal cell csarcinoma, squamous cell carcinoma and actinic keratosis cases. Turk Patoloji Derg., 2012, 28(2), 119-127.
[92]
Bundscherer, A.; Hafner, C.; Maisch, T.; Becker, B.; Landthaler, M.; Vogt, T. Antiproliferative and proapoptotic effect of rapamycin and celecoxib in malignant melanoma cell lines. Oncol. Rep., 2008, 19, 547-553.
[93]
Bhatt, R.S.; Merchan, J.; Parker, R.; Wu, H.K.; Zhang, L.; Seery, V.; Heymach, J.V.; Atkins, M.B.; McDermott, D.; Sukhatme, V.P. A phase 2 pilot trial of low-dose, continuos infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 2010, 116(7), 1751-1756.
[94]
Fegn, L.; Wang, Z. Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and ciclo-oxygenase-2. J. Laryngol. Otol., 2009, 123(8), 880-884.
[95]
Amini, S.; Viera, M.H.; Valins, W.; Berman, B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J. Clin. Aesthet. Dermatol., 2010, 3(6), 20-34.
[96]
Clarke, P. Nonmelanoma skin cancers – treatment options. Aust. Fam. Physician, 2012, 41(7), 476-480.
[97]
Feng, X.; Vyas, D.; Guan, B. Novel Target Therapy and Immunotherapy for Skin Cancer., US Pharm., 2012, 37(11) Suppl., 7-11.
[98]
Zanon, M.; Piris, A.; Bersani, I.; Vegetti, C.; Molla, A.; Scarito, A.; Anichini, A. Apoptosis protease activator protein-1 expression is dispensable for response of human cells to distinct proapoptotic agents. Cancer Res., 2004, 64(20), 7386-7394.
[99]
Simões, M.C.F.; Sousa, J.J.S.; Pais, A.A.C.C. Skin cancer and new treatment perspectives: A review. Cancer Lett., 2015, 357, 8-42.
[100]
Chakraborty, R.; Wieland, C.N.; Comfere, N.I. Molecular targeted therapies in metastatic melanoma. Pharm. Pers. Med., 2013, 6, 49-56.
[101]
Khan, M.H.; Alam, M.; Yoo, S. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers. Dermatol. Surg., 2011, 37(9), 1199-1209.
[102]
Heath, C.H.; Deep, N.L. Nabell, l.; Carroll, W.R.; Desmond, R.; Clemons, L. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 2013, 85(5), 1275-1281.
[103]
Bahner, J.D.; Bordeaux, J.S. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin. Dermatol., 2013, 31(6), 792-798.
[104]
Mandala, M.; Massi, D.; De Giorgi, V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Crit. Rev. Oncol. Hematol., 2013, 88(2), 318-337.
[105]
Kawczyk-Krupka, A.; Bugaj, A.M.; Latos, W.; Zaremba, K.; Sieron, A. Photodynamic therapy in treatment of cutaneous and choroidal melanoma. Photodiagn. Photodyn. Ther., 2013, 10(4), 503-509.
[106]
Rodust, P.M.; Fecker, L.F.; Stockfleth, E.; Eberle, J. Activation of mithocondrial apoptosis pathway in cutaneous squamous cell carcinoma cells by di- clofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w. Exp. Dermatol., 2012, 21(7), 520-525.
[107]
Kim, S.R.; Park, J.H.; Lee, M.E.; Park, J.S.; Park, S.C.; Han, J.A. Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblast in a catalytic activity-independent manner. Mech. Ageing Dev., 2008, 129(12), 706-713.
[108]
Li, F.; Liu, S.; Ouyang, Y.; Fan, C.; Wang, T.; Zhang, C.; Zeng, B.; Chai, Y.; Wang, X. Effect of celecoxib on proliferation, collagen expresion, ERK1/2 and SMAD2/3 phosphorylation in NIH/3T3 fibroblasts. Eur. J. Pharmacol., 2012, 678, 1-5.
[109]
DeCicco-Skinner, K.L.; Nolan, S.J.; Deshpande, M.M.; Trovato, E.L.; Dempsey, T.A.; Wiest, J.S. Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice. PLoS One, 2013, 8(2), e56212.
[110]
Escuin-Ordinas, H.; Atefi, M.; Fu, Y.; Cass, A.; Ng, C.; Huang, R.R.; Yashar, S.; Comin-Anduix, B.; Avramis, E.; Cochran, A.J.; Marais, R.; Lo, R.S.; Graeber, T.G.; Herschman, H.R.; Ribas, A. COX-2 inhibition prevents the apparence of cutaneous squamous cell carcinoma acelerated by BRAF inhibitors. Mol. Oncol., 2014, 8(2), 250-260.
[111]
Tang, J.Y.; Aszterbaum, M.; Athar, M.; Barsanti, F.; Cappola, C.; Estevez, N.; Hebert, J.; Hwang, J.; Khaimskiy, Y.; Kim, A.; Lu, Y.; So, P.L.; Tang, X.; Kohn, M.A.; McCulloch, C.E.; Kopelovich, L.; Bickers, D.R.; Epstein, E.H., Jr Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1*(+/−) humans and mice. Cancer Prev. Res. (Phila.), 2010, 3(1), 25-34.
[112]
Wilgus, T.A.; Koki, A.T.; Zweifel, B.S.; Rubal, P.A.; Oberyszyn, T.M. Chemotherapeutic efficacy of topical celecoxib in a murine model of Ultraviolet Light B-Induced skin cancer. Mol. Carcinog., 2003, 38(1), 33-39.
[113]
Pentland, A.P.; Schoggins, J.W.; Scott, G.A.; Khan, K.N.; Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis, 1999, 20(10), 1939-1944.
[114]
Fischer, S.M.; Conti, C.J.; Viner, J.; Aldaz, C.M.; Lubet, R.A. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis, 2003, 24(5), 945-952.
[115]
Bragagni, M.; Mennini, N.; Maestrelli, F.; Cirri, M.; Mura, P. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv., 2012, 19(7), 345-361.
[116]
Simonetti, L.D.; Gelfuso, G.M.; Barbosa, J.C.; Lopez, R.F. Assesment of the percutaneous penetration of cisplastin: The effect of monoolein and the drug skin penetration pathway. Eur. J. Pharm. Biopharm., 2009, 73(1), 90-94.
[117]
Tennenbaum, T.; Lowry, D.; Darwiche, N.; Morgan, D.L.; Gartsbein, M.; Hansen, L.; De Luca, L.M.; Hennings, H.; Yuspa, S.H. Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. Cancer Res., 1998, 58(7), 1435-1443.
[118]
Chun, K.S.; Kundu, J.K.; Park, K.K.; Chung, W.Y.; Surh, Y.J. Inhibition of phorbol ester–induced mouse skin tumor promotion and COX–2 expression by celecoxib: C/EPB as a potencial molecular target. Cancer Res. Treat., 2006, 38(3), 1252-1258.
[119]
Ochalek, M.; Podhaisky, H.; Ruettinger, H.H.; Neubert, R.H.; Wohlrab, J. SC lipid model membranes designed for studying impact of ceramides species on drug diffusion and permeation, part iii: influence of penetration enhancer on diffusion and permeation of models drugs. Int. J. Pharm., 2012, 436, 206-213.
[120]
Patlolla, R.R.; Desai, P.R.; Belay, K.; Singh, M.S. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials, 2010, 31(21), 5598-5607.
[121]
Ventura, C.A.; Tommasini, S.; Falcone, A.; Giannone, I.; Paolino, D.; Sdrafkakis, V.; Mondello, M.R.; Puglisi, G. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. Int. J. Pharm., 2006, 314(1), 37-45.
[122]
Engelbrecht, T.N.; Schroeter, A.; Hauss, T.; Neubert, R.H. Lipophilic penetration enhancers and their impact to the bilayer structure of stratum corneum lipid model membranes: Neutron diffraction studies based on the example Oleic Acid. Biochim. Biophys. Acta, 2011, 1808(12), 2798-2806.
[123]
Mélot, M.; Pudney, P.D.; Williamson, A.M.; Caspers, P.J.; Van Der Pol, A.; Puppels, G.J. Studying the effectiveness of penetration enhancers to deliver retinol through the stratum corneum by in vivo confocal raman spectroscopy. J. Control. Release, 2009, 138(1), 32-39.
[124]
Herai, H.; Gratieri, T.; Thomazine, J.A.; Bentley, M.V.; Lopez, R.F. Doxorubicin skin penetration from monolein–containing propylene glycol formulations. Int. J. Pharm., 2007, 329, 88-93.
[125]
Kreilgaard, M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Deliv. Rev., 2002, 54(Suppl. 1), S77-S98.
[126]
Pierre, M.B.; Dos Santos Miranda Costa, I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch. Dermatol. Res., 2011, 303, 607-621.
[127]
Srisuk, P.; Thongnopnua, P.; Raktanonchai, U.; Kanokpanont, S. Physico-chemical characteristics of methotrexate-entrapped oleic acid- containing deformable liposomes for in vitro transepidermal delivery targeting treatment. Int. J. Pharm., 2012, 427(2), 426-434.
[128]
Tan, A.; Simovic, S.; Davey, A.K.; Rades, T.; Boyd, B.J.; Prestidge, C.A. Silica nanoparticles to control the lipase-mediated digestion of lipid- based oral delivery systems. Mol. Pharm., 2010, 7(2), 522-532.
[129]
McCarron, P.A.; Marouf, W.M.; Donnelly, R.F.; Scott, C. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polimeric acid functionality. J. Biomed. Mater. Res., 2008, 87(4), 873-884.
[130]
Schneider, M.; Stracke, F.; Hansen, S.; Schaefer, U.F. Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinol, 2009, 1(4), 197-206.
[131]
Batheja, P.; Sheihet, L.; Kohn, J.; Singer, A.J.; Michniak-Kohn, B. Topical drug delivery by a polimeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J. Control. Release, 2011, 149(2), 159-167.
[132]
Mehnert, W.; Mäder, K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
[133]
Hussain, Z.; Katas, H.; Mohd Amin, M.C.; Kumolosasi, E.; Buang, F.; Sahudin, S. Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: An ex vivo and in vivo study using an NC/Nga mouse model. Int. J. Pharm., 2013, 444(1-2), 109-119.
[134]
Estracanholli, E.A.; Praça, F.S.G.; Cintra, A.B.; Pierre, M.B.R.; Lara, M.G. Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies. AAPS PharmSciTech, 2014, 15(6), 1468-1475.
[135]
Dante, M.C.L.; Borgheti-Cardoso, L.N.; Fantini, M.C.A.; Praça, F.S.G.; Medina, W.S.G.; Pierre, M.B.R.; Lara, M.G. Liquid crystalline systems based on glyceryl monooleate and penetration enhancers for skin delivery of celecoxib: characterization, In Vitro drug release, and in vivo studies. J. Pharm. Sci., 2017, pii: S0022- 3549(17), 30778-30785

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version309msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[17:52:48] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[17:52:48] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[17:52:48] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (100ms)time
  • Application (209ms)time
  • 1 x Application (67.6%)
    209ms
    1 x Booting (32.4%)
    100ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    37 statements were executed, 4 of which were duplicates, 33 unique. Show only duplicated136ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('51435153','',1,1739987568,1739987568) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1739987568
      1.08msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('51435153','/article/90075',1,1739987568,1739987568)
      200μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 51435153 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51435153) limit 1
      13.14msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 51435153
      • 1: 51435153
      • 2: 51435153
      • 3: 51435153
      • 4: 51435153
      • 5: 51435153
      • 6: 51435153
      • 7: 51435153
      • 8: 51435153
      • 9: 51435153
      • 10: 51435153
      • 11: 51435153
      • 12: 51435153
      • 13: 51435153
      • 14: 51435153
      • 15: 51435153
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=90075
      810μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 7 limit 1
      1.17msalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 7
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and sj.journal_id!=7 group by `j`.`nid`) as `aggregate_table`
      1.47msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and sj.journal_id!=7 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.2msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      2.3msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      2msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '90075'
      1.51msalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 90075
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '90075'
      3.92msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 90075
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '90075' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      3.55msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 90075
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      300μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      640μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 7 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      31.95msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 7 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      9.44msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 7 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      7.25msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 90075 limit 1
      230μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 90075
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 90075 and content_type = 'article' order by status desc limit 1
      1.25msalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 490 and content_id!=90075 and cd.content_type = 'article' order by rand() limit 20
      42.26msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 161688 limit 1
      220μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 161688
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      210μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CCDT' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      300μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CCDT
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '90075' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      380μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '8762' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      330μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '2548' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      340μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2548) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2548) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2548)
      2.04msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 8762) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 8762) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 8762)
      600μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 90075) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 90075) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51435153 and j.to_ip >=51435153 )) and ((j.from_date <= 1739987568 and j.to_date >= 1739987568 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 90075)
      570μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '5' and is_uploaded = 1 and issue_id = 8762 order by cast(first_page as SIGNED) desc limit 1
      520μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 5
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '16' and is_uploaded = 1 and issue_id = 8762 order by cast(first_page as SIGNED) asc limit 1
      440μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 16
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      170μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      190μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 90075 limit 1
      1.37msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 90075
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 7 and `b`.`banner_from_date` <= 1739987568 and `b`.`banner_to_date` >= 1739987568 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.16msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 7
      • 3: 1739987568
      • 4: 1739987568
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 7 and `b`.`banner_from_date` <= 1739987568 and `b`.`banner_to_date` >= 1739987568 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.08msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 7
      • 3: 1739987568
      • 4: 1739987568
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='2cd3a99922d4e478ab4f832170753b0b'
      240μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
    App\Models\MultiLangArticle
    1MultiLangArticle.php#?
        _token
        k4SCs4uA3iwVANXI81gJUXIukipvqOYdGfp010Nx
        uc_cart_id
        2cd3a99922d4e478ab4f832170753b0b
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/90075" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/90075
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:8 [ "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        []
        
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Wed, 19 Feb 2025 17:52:48 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6InppU1V1dkpCdDZiWHgyRWEzbEwrM1E9PSIsInZhbHVlIjoiVVVGTlR5alVTMDMvL1VUUVRtZFJPUHZVb3pJcURFYzRBWGZpeXVzLzNQdFN4TmlQWFQ0VmFCaERkQTBranJja00wa1NTdll0ZjZMQlNPbDJlaG1YeStoVDNUNm1DcXFzeGRZUjZJd1BUOG02UnhmSzVIR3BTcC8zYnRnV09wZlciLCJtYWMiOiI5YWJmYjg0N2RkMzEyZmViMDU4MDdhNzAxNTMwMzY4M2JkMTRiZWM5NTlkYWE3OWY4MmNiYWY0N2Q1NzdjNTc3IiwidGFnIjoiIn0%3D; expires=Sat, 22 Feb 2025 05:52:48 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6InppU1V1dkpCdDZiWHgyRWEzbEwrM1E9PSIsInZhbHVlIjoiVVVGTlR5alVTMDMvL1VUUVRtZFJPUHZVb3pJcURFYzRBWGZpeXVzLzNQdFN4TmlQWFQ0VmFCaERkQTBranJja00wa1NTd" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkdYV1lMTTR1R2EvV04yU1plSmV5dWc9PSIsInZhbHVlIjoicHBLZFNPbjdGbVdGOFoybXJJYWt0cjJYckZhNTRCbWJyTUV1THkyaFZaTVd1d2diVkR4ejJEaTUyNElMemZScVhqbXZYZi9DVmRpYmRNKzdYOFJWM25sMzhTK29EeXNGdHFQWVZDTTdTaGNJOTdlUVdhL3IvblFDUlVhVk1jUHYiLCJtYWMiOiJhNDMxYjA1OWFkNzNiMjg4NWFhYjkzZDE3ZjU3Yjk1YWM2MTZiNmQ5N2VjMzNkYTc1MzkzYmI3ZTdjMmRmZTgwIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6IkdYV1lMTTR1R2EvV04yU1plSmV5dWc9PSIsInZhbHVlIjoicHBLZFNPbjdGbVdGOFoybXJJYWt0cjJYckZhNTRCbWJyTUV1THkyaFZaTVd1d2diVkR4ejJEaTU" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6InppU1V1dkpCdDZiWHgyRWEzbEwrM1E9PSIsInZhbHVlIjoiVVVGTlR5alVTMDMvL1VUUVRtZFJPUHZVb3pJcURFYzRBWGZpeXVzLzNQdFN4TmlQWFQ0VmFCaERkQTBranJja00wa1NTdll0ZjZMQlNPbDJlaG1YeStoVDNUNm1DcXFzeGRZUjZJd1BUOG02UnhmSzVIR3BTcC8zYnRnV09wZlciLCJtYWMiOiI5YWJmYjg0N2RkMzEyZmViMDU4MDdhNzAxNTMwMzY4M2JkMTRiZWM5NTlkYWE3OWY4MmNiYWY0N2Q1NzdjNTc3IiwidGFnIjoiIn0%3D; expires=Sat, 22-Feb-2025 05:52:48 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6InppU1V1dkpCdDZiWHgyRWEzbEwrM1E9PSIsInZhbHVlIjoiVVVGTlR5alVTMDMvL1VUUVRtZFJPUHZVb3pJcURFYzRBWGZpeXVzLzNQdFN4TmlQWFQ0VmFCaERkQTBranJja00wa1NTd" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkdYV1lMTTR1R2EvV04yU1plSmV5dWc9PSIsInZhbHVlIjoicHBLZFNPbjdGbVdGOFoybXJJYWt0cjJYckZhNTRCbWJyTUV1THkyaFZaTVd1d2diVkR4ejJEaTUyNElMemZScVhqbXZYZi9DVmRpYmRNKzdYOFJWM25sMzhTK29EeXNGdHFQWVZDTTdTaGNJOTdlUVdhL3IvblFDUlVhVk1jUHYiLCJtYWMiOiJhNDMxYjA1OWFkNzNiMjg4NWFhYjkzZDE3ZjU3Yjk1YWM2MTZiNmQ5N2VjMzNkYTc1MzkzYmI3ZTdjMmRmZTgwIiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6IkdYV1lMTTR1R2EvV04yU1plSmV5dWc9PSIsInZhbHVlIjoicHBLZFNPbjdGbVdGOFoybXJJYWt0cjJYckZhNTRCbWJyTUV1THkyaFZaTVd1d2diVkR4ejJEaTU" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "k4SCs4uA3iwVANXI81gJUXIukipvqOYdGfp010Nx" "uc_cart_id" => "2cd3a99922d4e478ab4f832170753b0b" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/90075" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-19 17:52:48GET/article/90075314372